Pain and analgesics

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 5 (1 votes)

This article have been viewed 6530 times

Michael C. Lee, Mark Abrahams

Pain and analgesics

Nociception

Pain alerts us to ongoing or potential tissue damage and the ability to sense pain is vital to our survival. The physiological process by which pain is perceived is known as nociception. While the neurobiology of nociception is complex, its appreciation provides a useful framework for understanding the way analgesics work (Fig. 18.2).

Our nervous system is alerted to actual or potential tissue injury by the activation of the peripheral terminals of highly specialised primary sensory neurones called nociceptors. Nociceptors have unmyelinated (C-fibre) or thinly myelinated (Aδ-fibre) axons. Their cell bodies lie in the dorsal root ganglia of the spinal cord or in the trigeminal ganglia. Different nociceptors encode discrete intensities and modalities of pain, depending upon their expression of ion-channel receptors. These receptors are transducers. They convert noxious stimuli into action potentials. Some of these transducers have been identified, including those that respond to heat (> 46°C), cold (< 10°C) and direct chemical irritants such as capsaicin.

Action potentials that result from the transduction of noxious stimuli are conducted along the axon of the sensory neurone into the spinal cord. Conduction of the action potentials in sensory neurones depends on voltage-gated sodium channels, including two that are predominately expressed in nociceptors; Nav1.7 and Nav1.8.

The central terminal of the nociceptor makes synaptic contact with dorsal horn neurones within the spinal cord. Glutamate, an amino acid, is the main excitatory neurotransmitter released at these synapses. Its release can be inhibited by ligands that act to activate receptors found on the central terminal of the nociceptors (pre-synaptic inhibition). These include the opioids, cannabinoids, γ-aminobutyric acid (GABA)-receptor ligands and the anticonvulsants, gabapentin and pregabalin. Opioids and GABA also influence the action of glutamate on the dorsal horn neurones. They act on post-synaptic receptors to open potassium or chloride channels. This results in hyperpolarisation of the neurone, which inhibits its activity.

Other neurotransmitters may also be released by the central terminal of the nociceptors. For example, substance P is released during high-intensity and repetitive noxious stimulation. It mediates slow excitatory post-synaptic potentials and results in a localised depolarisation that facilitates the activation of N-methyl-D-aspartate (NMDA) receptors by glutamate. The end-result is a progressive increase in the output from dorsal horn neurones. This amplified output is thought to be responsible for the escalation of pain when the skin is repeatedly stimulated by noxious heat – a phenomenon known as wind-up.

Nociceptive output from the spinal cord is further modulated by descending inhibitory neurones that originate from supraspinal sites such as the periaqueductal gray or the rostral ventromedial medulla and terminate on nociceptive neurones in the spinal cord as well as on spinal inhibitory interneurones that store and release opioids. Stimulation of these brain regions, either electrically or chemically (e.g. opioids), produces analgesia in humans. Transmission through these inhibitory pathways is facilitated by monoamine neurotransmitters such as noradrenaline/norepinephrine and serotonin.

Finally, dorsal horn neurones send projections to supraspinal areas in the brainstem, hypothalamus, and thalamus and then, through relay neurones, to the cortex where the sensation of pain is perceived. The mechanism by which the cortex produces the conscious appreciation of pain is the focus of much research.

Classification of clinical pain

Rational pharmacological treatment of clinical pain depends on a number of factors, including the underlying cause and duration of pain, the patient’s general medical condition and prognosis. Clinical pain is generally divided into three broad categories; acute, chronic, and cancer-related.

Evaluation of pain

Achieving optimal pharmacological management of the patient’s pain will depend on the type and cause of pain, as well as the psychological and physical condition of the patient. A comprehensive evaluation of the pain is, therefore, essential if we are to treat the patient successfully and safely. Underlying organic pathology must be excluded unless an obvious cause of pain is apparent (e.g. after recent surgery or trauma). The presence of organic pathology should also be suspected if the patient’s pain presents in an unusual way, or is of a much greater magnitude than would normally be expected from the assumed pathology.

Once an organic explanation has been eliminated, additional tests are unhelpful. The illusory sense of progress such tests provide for both physician and patient may perpetuate maladaptive behaviour and impede the return to more normal function.

The evaluation of persistent pain should include pain location, quality, severity, duration, course, timing (including frequency of remissions and degree of fluctuation), exacerbating and relieving factors, and co-morbidities associated with the pain (with emphasis on psychological issues, depression, and anxiety). The efficacy and adverse effects of currently or previously used drugs and other treatments should also be determined.

If appropriate, the patient should be asked if litigation is ongoing or whether financial compensation for injury will be sought. A personal or family history of chronic pain can often give insight into the current problem. The patient’s level of function should be assessed in detail, focusing on family relationships (including sexual), social network, and employment or vocation. The interviewer should elicit how the patient’s pain affects the activities of normal living.

It is also important to determine what the pain means to the patient. In some patients, reporting pain may be more socially acceptable than reporting feelings of depression or anxiety. Pain and suffering should also be distinguished. In cancer patients, in particular, suffering may be due as much to loss of function and fear of impending death as to pain. The patient’s expression of pain represents more than the pathology intrinsic to the disease.

Thorough physical examination is essential, and can often help to identify underlying causes and to evaluate, further, the degree of functional impairment. A basic neurological examination may identify features associated with neuropathic pain including:

Non-opioid analgesics

NSAIDs (non-steroidal anti-inflammatory drugs)

Mechanism of analgesia

Endothelial damage produces an inflammatory response in tissues. Damaged cells release intracellular contents, such as adenosine triphosphate, hydrogen and potassium ions. Inflammatory cells recruited to the site of damage produce cytokines, chemokines and growth factors. A profound change to the chemical environment of the peripheral terminal of nociceptors occurs. Some factors act directly on the nociceptor terminal to activate it and produce pain, and others sensitise the terminal so that it becomes hypersensitive to subsequent stimuli. This process is known as peripheral sensitisation.

Prostanoid is a major sensitiser that is produced at the site of tissue injury. NSAIDs act by inhibiting cyclo-oxygenase, an enzyme involved in the production of prostanoid, as well as other prostaglandins. This enzyme has a number of isoforms, the most studied being cyclo-oxgenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2). Their actions are inhibited by NSAIDs (see Ch. 16). Increased COX-2 production is induced by tissue injury and accounts for the efficacy of COX-2-specific inhibitor drugs (COXIBs). The inhibitory effect of NSAIDs on the production of other prostaglandins is responsible for the common side-effects of these drugs. Among other functions, the prostaglandins produced by cyclo-oxygenase act to protect the gastric mucosa, maintain normal blood flow in the kidney and preserve normal platelet function. Inhibition of prostaglandin production, therefore, can cause gastric irritation, damage to the kidney and an increased risk of bleeding.

Opioid analgesics

Opium (the dried juice of the seed head of the opium poppy) was used in prehistoric times. Modern medical practice still benefits from the use of its alkaloids, employing them as analgesics, tranquillisers, antitussives and in the treatment of diarrhoea.

The principal active ingredient in crude opium was isolated in 1806 by Friedrich Sertürner, who tested pure morphine on himself and three young men. He observed that the drug caused cerebral depression and relieved toothache, and named it after Morpheus, the Greek god of dreams. Opium contains many alkaloids, but the only important opiates (drugs derived from opium) are morphine (10%) and codeine. Papaverine is occasionally used as a vasodilator.

Opioid is a generic term for natural or synthetic substances that bind to specific opioid receptors in the CNS, producing an agonist action.

Systemic effects of opioid analgesics

Central nervous system

Opioids reduce the intensity and unpleasantness of pain. Patients taking opioid analgesics often report less distress, even when they can still perceive pain. Sedation occurs frequently, particularly in the early stages of treatment, but often resolves although it can remain a problem, especially at higher doses, and is a common cause of drug discontinuation in the chronic pain population.

The sensitivity of the respiratory centre to hypercarbia and hypoxaemia is reduced by opioids. Hypoventilation, due to a reduction in respiratory rate and tidal volume, ensues. Cough is inhibited by a central action. Prolonged apnoea and respiratory obstruction can occur during sleep. These effects are more pronounced when the respiratory drive is impaired by disease, for example in chronic obstructive pulmonary disease, obstructive sleep apnoea and raised intracranial pressure.

Opioid-related respiratory depression is more common in patients being treated for acute pain than in patients established on long-term opioids. Respiratory depression in use relates to high blood opioid concentrations, for example with an inappropriately large dose that fails to account for differences in patient physiology (e.g. in hypovolaemic trauma or the elderly), or because the patient is unable to excrete the drug efficiently (as a consequence of renal impairment). Respiratory depression is unusual in patients established on long-term opioids due to the development of tolerance. Sudden changes to the patient’s physiological state (e.g. the development of acute renal failure) may produce increases in blood opioid concentration and precipitate toxic effects.

Nausea and vomiting commonly accompany opioids used for acute pain. The mechanism may be activation of opioid receptors within the chemoreceptor trigger zone within the medulla, although opioid effects on the gastrointestinal tract and vestibular function probably play a role. Antiemetics are effective.

Miosis occurs due to an excitatory effect on the parasympathetic nerve innervating the pupil. Pin-point pupils are characteristic of acute poisoning; at therapeutic doses the pupils are merely smaller than normal.

Route of administration

The oral route is preferred as it is simple, non-invasive and relatively affordable. It requires little in the form of direct medical supervision or complex delivery equipment. The slower onset of action renders this route less convenient for use in acute pain. The oral route is also unsuitable when patients suffer from emesis, dysphagia, gastrointestinal obstruction or malabsorption or in acute trauma where the patient may have delayed gastric emptying.

If parenteral administration is necessary, the intravenous route is preferable to intramuscular injection for repeated boluses because it is less painful. Also, intramuscular or subcutaneous routes of administration should not be used if the patient is peripherally vasoconstricted (e.g. in the acute trauma patient), as the establishment of normal peripheral blood flow, as the patient is resuscitated, may result in a sudden redistribution of the drug to the central circulation. Continuous intravenous or subcutaneous infusion should be considered if repeated parenteral doses produce a prominent bolus effect (i.e. toxicity) at peak levels early in the dosing interval or breakthrough pain at trough levels. Patient-controlled analgesia (PCA) systems (in which the patient can trigger additional drug delivery) can be added to an infusion to provide supplementary doses. These systems are safe for both home and hospitalised patients, but are contraindicated for sedated and confused patients.

Epidural and intrathecal administration of opioids requires special expertise. The dorsal horn of the spinal cord is rich in opioid receptors, and equivalent analgesia can be provided using a lower dose of opioid, resulting in fewer systemic side-effects. However, rostral spread of the drug can result in delayed toxicity (e.g. respiratory depression) during acute administration, and the cost of infusion systems, staffing and monitoring must also be taken into account. The use of intraventricular morphine appears to be beneficial in treating recalcitrant pain due to head and neck malignancies and tumours (e.g., superior sulcus tumours, breast carcinoma) that affect the brachial plexus.

Pharmacology of individual opioids

Opioid agonist drugs

Partial agonist opioid analgesics

Opioids with action on other systems

Pethidine (meperidine)

Pethidine (meperidine) was discovered in 1939 during a search for atropine-like compounds. Its use as a treatment for asthma was abandoned when its opioid agonist properties were appreciated.

Pethidine is primarily a μ-receptor agonist. Despite its structural dissimilarity to morphine, pethidine shares many similar properties, including antagonism by naloxone. It is extensively metabolised in the liver and the parent drug and metabolites are excreted in the urine. Normeperidine is a pharmacologically active metabolite. It can cause central excitation and, eventually, convulsions, if it accumulates after prolonged intravenous administration or in renal impairment.

Pethidine has atropine-like effects, including dry mouth and blurred vision (cycloplegia and sometimes mydriasis, though usually miosis). It can produce euphoria and is associated with a high incidence of dependence. Its use as an analgesia in obstetric practice was based on early clinical research which showed that, unlike morphine, pethidine did not appear to delay labour. However, the doses of pethidine used in these early studies were low and it is now established that pethidine confers no added advantage over other opioids at higher equi-analgesic doses.

Pethidine is eight to ten times less potent than morphine, has poor and variable oral absorption, with a short duration of action in the range of 2–3 h. For all these reasons, it is recommended that pethidine should be avoided if alternatives are available.3

Choice of opioid analgesic

An opioid may be preferred because of favourable experience, lower cost (methadone is least expensive), availability, route of administration or duration of action. Opioids with a short half-life (morphine and diamorphine) should be used as first-line agents for acute pain but may be replaced with longer-acting drugs if pain persists.

Knowledge of equi-analgesic doses of opioids is essential when changing drugs or routes of administration (Tables 18.3 and 18.4). Cross-tolerance between drugs is incomplete, so when one drug is substituted for another, the equi-analgesic dose should be reduced by 50%. The only exception is methadone, which should be reduced by 75–90%. Opioid rotation is commonly used in cancer-related and chronic non-malignant pain as a means of reducing side-effects and limiting the development of tolerance.

Table 18.3 Relative potency of opioids

Drug Oral:parenteral potency ratio* Parenteral potency relative to morphine**
Morphine 1:6 1.0
Codeine 2:3 0.1
Hydromorphone 1:5 6.0
Meperidine 1:4 0.15
Oxycodone 1:2 1.0
Methadone 1:2 1.0

* Oral–parenteral ratio: for example, morphine is six times more potent parenterally than orally.

** Potency relative to morphine: for example, hydromorphone is six times more potent than an equal dose of morphine when given parenterally.

(Mitchell J P 1989 General care of the patient. In: Claiborne D, Ridner M (eds) Manual of Medical Therapeutics, 26th edn. Little, Brown, p. 5.)

Table 18.4 Opioid oral analgesic equivalents

Analgesic Single dose Equi-analgesic dose Oral morphine
Codeine 60 mg 5 mg
Dihydrocodeine 60 mg 8 mg
Tramadol 50 mg 10 mg
Meptazinol 200 mg 8 mg
Buprenorphine
sublingual
200 micrograms 10 mg
Hydromorphone 1.3 mg 10 mg
Methadone 1 mg 10 mg
Oxycodone 5 mg 10 mg

Tolerance, dependence and addiction

Although the use of strong opioid analgesics in cancer-related pain is well established, physicians are often reluctant to prescribe opioids in acute, and especially in chronic, non-malignant pain. Patients (and their families, friends and employers) are, likewise, wary about the long-term use of opioids. The reasons for this reluctance may stem from previous experiences of the genuine problems associated with long-term opioid use in patients or, more often, due to the perception of opioids as dangerous and addictive drugs. Patients and physicians also frequently confuse tolerance and dependence with drug addiction.

Co-analgesics

Co-analgesics (adjuvant analgesics) are important for the treatment of cancer-related and chronic non-malignant pain. These agents provide an ‘opioid-sparing’ effect and are effective for the treatment of neuropathic pain associated with many cancers. In chronic non-malignant pain, co-analgesics are frequently used as ‘first-line’ drugs, and form the mainstay of treatment for chronic neuropathic pain. As co-analgesics are generally used in other medical conditions (e.g. as anticonvulsants or antidepressants), their basic pharmacology will be covered in the relevant chapters elsewhere. This chapter highlights the use of co-analgesics in the context of pain management.

Multipurpose adjuvant analgesics

Adjuvant analgesics used in neuropathic pain

Antidepressants

At present, the evidence for analgesic efficacy is greatest for the tertiary amine tricyclic drugs, such as amitriptyline, doxepin and imipramine. The secondary amine tricyclic antidepressants (such as desipramine and nortriptyline) have fewer side-effects and are preferred when there are serious concerns about sedation, anticholinergic effects or cardiovascular toxicity. Dual-reuptake inhibitors (venlafaxine, duloxetine) may be beneficial for patients who obtain relief from tricyclics but find the adverse effects a problem. Duloxetine is currently licensed for the treatment of pain from diabetic neuropathy and fibromyalgia and has been shown to be effective in clinical trials. There is little evidence, however, to suggest that duloxetine is more efficacious compared to tricyclic antidepressant drugs for the treatment of neuropathic pain.

The dose of duloxetine required to treat pain is 60–120 mg, which also has clinically relevant antidepressant effects. This is in contrast to other antidepressant drugs used in neuropathic pain where the analgesic effect of the drugs occurs at a smaller dose and within a shorter time from onset (1–2 weeks) than any antidepressant effect. The drugs should be started at a low dose to minimise initial side-effects (e.g. amitriptyline 10 mg daily in the elderly and 10–25 mg daily in younger patients). Education of the patient is essential. They should be informed that the analgesic effect of the antidepressant medication can take days or weeks to develop, and that the drug must be taken on a regular basis for effect. It is common for patients to report taking the medication intermittently as a supplement to simple analgesics ‘when the pain is bad’. Patient compliance is often improved when physicians emphasise that the drugs are being prescribed for their analgesic effects and not for their antidepressant properties.

Abrupt withdrawal of the antidepressant drugs should be avoided as it can cause a variety of unpleasant symptoms, thought to be related to rebound cholinergic activity. These include vivid dreams, restlessness and gastrointestinal hyperactivity. These symptoms can be minimised if the drug dose is reduced gradually at intervals of 5–10 days.

Anticonvulsants

In 1853, Alfred Trousseau, then director of the medical clinic at the Hôtel-Dieu in Paris, suggested that painful paroxysms seen in trigeminal neuralgia were due to discharges in the trigeminal system that were similar to the neuronal discharges seen in epilepsy. Trousseau’s hypothesis was tested by Bergouigan who successfully used phenytoin to treat trigeminal neuralgia. Carbamazepine was studied in the same condition during a placebo-controlled double-blind design that was among the first of its kind in pain medicine. Since then, anticonvulsants have been extensively used in a wide variety of neuropathic pain syndromes, particularly those associated with ‘lancinating’ or ‘shooting’ pain. Animal studies have shown that peripheral nerve fibres in persistent pain syndromes have altered expression of certain ion channels, particularly novel sodium channels, and N-type calcium channels.

Carbamazepine, phenytoin and sodium valproate have been used for many years to treat neuropathic pain. However, carbamazepine remains the only anticonvulsant licensed within the UK for the treatment of trigeminal neuralgia. All anticonvulsants produce side-effects such as dizziness and drowsiness. Carbamazepine, in particular, may suppress bone marrow function and cause hyponatraemia. Its use requires regular blood monitoring.

Gabapentin and pregabalin are newer anticonvulsant agents that show good efficacy in clinical trials of neuropathic pain. These drugs bind to the α2δ-1 subunit of voltage-dependent calcium channels and may work by preventing the formation of excitatory synapses within the central nervous system.5 Gabapentin is generally better tolerated than the older anticonvulsants and has a licence in the UK for the treatment of neuropathic pain. It is not metabolised by the liver and has few clinically significant drug interactions. It should be started at a dose of 300 mg at night (100 mg in the elderly) and titrated upwards as tolerated or to a dose of 600–1200 mg three times daily. A saturable gut transport mechanism limits bio-availability at high oral doses (but also protects against overdosage). Pregabalin shares a similar mode of action to gabapentin, but has the advantage of more linear pharmacokinetics and can be given as a twice daily preparation (normal maintenance dose up to 300 mg twice daily).

Cannabinoids

Delta-9-tetrahydrocannabinol (THC) is the only constituent of cannabis with with clinically significant analgesic properties. THC is a partial agonist at the cannbinoid-1 receptor (CB-1r), which mediates its analgesic effects. The CB-1r is widely expressed throughout the CNS (including the brain), which accounts for the psychotrophic effects of THC. Clinical trials continue to suggest that THC is useful for the treatment of refractory chronic pain, particularly in multiple sclerosis, cancer or HIV. Additionally, the cannabinoid is an antiemetic and stimulates the appetite.

THC and related cannabinoids are formulated for the oral and oromucosal routes. The oral preparations are pure and synthetically derived. The oromucosal preparation Sativex® is plant-derived and comprises THC and cannabidiol (CBD) in equal proportions. Cannabidiol does not possess analgesic properties but may attenuate the psycho-activity of THC via an anxiolytic effect. Sativex® is currently licensed in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis and pain from cancer.

The oral bio-availability of THC is poor and varies highly between individuals. Peak plasma concentration improves with fasting and occurs 2–4 h after drug ingestion. The oromucosal route avoids the hepatic first pass effect and consequently has a quicker onset and greater bio-availability. Consequently, patients may themselves adjust the dose of Sativex® until pain relief is achieved with tolerable side-effects.

Ziconotide

Ziconotide (previously called SNX-111) is the synthetic form of the hydrophilic conopeptide ω-MVIIA, which is found in the venom of the Pacific fish-hunting snail, Conus magus. Notably, ziconotide is the only truly novel analgesic that has emerged from decades of pharmaceutical research and development.

Ziconotide binds reversibly and tightly to a subset of voltage-sensitive calcium channels (N-type channels) which are found in the dorsal horn of the spinal cord and localised to the pre-synaptic central terminals of primary afferent neurones. The binding of ziconotide inhibits these channels, which reduces nociceptive transmission at the spinal level. N-type calcium channels are found throughout the CNS and account for the adverse effects of ziconotide. Common adverse effects are dizziness, nausea, confusion, and headache. More severe, but rare side-effects are hallucinations, thoughts of suicide, new or worsening depression. Consequently, the drug is contraindicated in patients with a history of psychosis, schizophrenia, clinical depression or bipolar disorder.

Ziconotide is only administered intrathecally to minimise adverse effects. The optimal dose is achieved by slow titration over weeks as an infusion via an intrathecal pump. The method of delivery is complex, costly and invasive. Consequently, ziconotide is only approved for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who have been shown to be intolerant of, or refractory to, other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Drug tolerance does not occur and there are minimal withdrawal effects after prolonged infusion.

Pharmacotherapy of acute migraine headaches

Migraine is characterised by episodic attacks of moderate-severe throbbing headache with a number of associated symptoms that include nausea, vomiting, photophobia and phonophobia. In around one third of patients with migraine, the headache can be accompanied by focal neurological symptoms (aura). In Europe and the USA, about 18% of women and 6% of men suffered at least one migraine attack in the past year. Migraine has been ranked among the world’s most disabling medical illnesses. Its socioeconomic impact is substantial, with an estimated annual cost of $17 billion for treatment costs alone.

The pathophysiology of migraine is complex but a likely causative factor is the release of vasoactive peptides from the sensory nerve terminals that innervate meningeal blood vessels, causing dilatation of the arteries in the meninges, perivascular inflammation and amplification of the nociceptive afferent nerve supply. Sensory input from dural and cerebrovascular sensory fibres is amplified and perceived as pain (allodynia). Activation of the sympathetic nervous system is the likely cause of autonomic symptoms such as nausea and vomiting. Sensory symptoms (aura) are produced by a transient, spreading disturbance in cortical function. Migraine possesses features of inflammatory and functional pain, as well as objective neurologic dysfunction. Diagnosis is based on the headache’s characteristics and associated symptoms.6

Selective 5-HT1 agonists (triptans)

Triptans are serotonin (5-hydroxytryptamine or 5-HT) antagonists with high affinity for 5-HT1B or 5-HT1D receptors. Action at the 5-HT1B receptors on blood vessels produces cranial vasoconstriction. Action at presynaptic 5-HT1D receptors inhibits the release of vasoactive peptides and nociceptive neurotransmitters. Recent comparative randomised trials of triptans show efficacy rates similar to those of simple analgesics and NSAIDs. In patients without cardiovascular contraindications, triptans are safe, effective and appropriate first-line treatments for patients who have a moderate to severe headache and in patients where simple or combination analgesics have failed to provide adequate relief. Triptan therapy is most effective when used early when the headache is mild, but it is uncertain if they are best used after the resolution of the aura and the optimal timing is probably patient-dependent.

The choice of triptan also depends upon patient preference, as well as the character, duration and severity of the headache, convenience and cost. Non-oral administration may be beneficial in cases when the headache intensifies rapidly, or severe nausea and emesis are early features of the headache. Only sumatriptan is available for parenteral administration.

The onset of action of most triptans is 20–60 min (10 min for sumatriptan). If necessary, patients can take another dose after 2 or 4 h. If the appropriate dose of triptan is ineffective or has unacceptable side-effects, consider a switch to an alternative triptan formulation. The drugs can be used in combination with other simple analgesics, NSAIDs and antiemetics. There is a risk of developing serotonin syndrome (see p. 318) if given in combination with other serotonin-reuptake inhibitor drugs (e.g. SSRI or MAOI antidepressants). While the risk of causing birth defects is probably low, triptans should not be used routinely during pregnancy.

Minor adverse effects such as flushing and neck or chest tightness are very common. In most cases, this is not caused by coronary vasoconstriction. There are reported cases of serious cardiovascular events and triptans should be avoided in patients who have, or are at high risk of developing, coronary heart disease.

Frequent use of triptans is also associated with the development of analgesic-associated chronic daily headache and, in general, the use of the drugs should be limited to an average of 2 days per week.

Preventive treatment for migraine

For patients who are unable to achieve adequate pain relief with the use of the standard analgesic medications and triptans, the use of medications to reduce the frequency and intensity of migraine attacks may be appropriate. Other indications for preventative medications include troublesome adverse events from standard drug therapies, acute drug overuse, very frequent headaches (more than two per week), special circumstances such as hemiplegic migraine, or attacks with a risk of permanent neurological injury.

Medications used for prophylaxis include β-adrenergic blockers, non-steroidal anti-inflammatory drugs, and antineuropathic medications such as the antidepressants, calcium-channel antagonists and anticonvulsants. Those with the best documented effectiveness are β-adrenergic blockers, pizotifen, and the anticonvulsant drugs, sodium valproate and topiramate.

Choice of migraine prophylactic agent is based on effectiveness, adverse events, and coexistent and co-morbid conditions. Women of childbearing potential should be educated about the risk of drugs in pregnancy and encouraged to consider contraception. Because of the risks of adverse effects, especially drowsiness, on commencing treatment, all the migraine prophylactic drugs should be started at a low dose and increased slowly until therapeutic effects develop or the maximum dose is reached. A full therapeutic trial may take 2–6 months. Patients should try to avoid overusing drugs for acute attacks during the trial period. If headaches are well controlled, treatment can be tapered down and may be discontinued if the patient remains symptom-free.

1 Pope John Paul II. Letter handed to John Bonica on the occasion of the Fifth World Congress on Pain. In: Benedetti C, Chapman C R, Giron G (eds) 1990 Opioid Analgesia: Recent Advances in Systemic Administration. Advances in Pain Research and Therapy, vol. 14. Raven Press, New York.

2 ‘Another event at Elsterhorst had a marked effect on me. The Germans dumped a young Soviet prisoner in my ward late one night. The ward was full, so I put him in my room as he was moribund and screaming and I did not want to wake the ward. I examined him. He had obvious gross bilateral cavitation and a severe pleural rub. I thought the latter was the cause of the pain and the screaming. I had no morphia, just aspirin, which had no effect. I felt desperate. I knew very little Russian then and there was no one in the ward who did. I finally instinctively sat down on the bed and took him in my arms, and the screaming stopped almost at once. He died peacefully in my arms a few hours later. It was not the pleurisy that caused the screaming but loneliness. It was a wonderful education about the care of the dying. I was ashamed of my misdiagnosis and kept the story secret.’ Cochrane A L (with M Blythe). London: BMJ (Memoir Club), 1989, p. 82.

3 World Health Organization 1996.

4 Opioids for persistent pain. 2010 Guidelines British Pain Society.

5 Published in Cell 2009.

6 Headache Classification Subcommittee of the International Headache Society 2004 International classification of headache disorders. Cephalalgia 24(Suppl.1):9–160.